$30MM per 1% of the market in an earlier post. 20% of the market would equate roughly to $600MM revenue. Cut that in half to remove taxes and expenses and you have a net earn of $300MM. Divided by 141MM shares and you have an EPS of 2.12. Biotechs have P/E's in the hundreds, so a low one would be 100= $212 share price. 50% market share would be a crazy number.
What's that about not being able to support an $8B market cap?